Wahlin et al. evaluated the prognostic influence of pretransplant characteristics on response and survival in MM patients (N = 104) receiving uniform pretransplant treatment consisting of VAD (vincristine, doxorubicin, and dexamethasone) regimen, stem cell mobilization, and conditioning with melphalan 200 mg/m2 and reported that patients with higher harvest yields of CD34+ cells (> 11.8 × 106 cells/kg) had better OS [13]. The gene discussed is CD34; the disease is Miyoshi myopathy.